In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in ALL
Poster Session #2
Jointly provided by Integrity Continuing Education, Inc. and Bonum Continuing Education LLC.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Program Overview
Current first-line treatment of acute lymphoblastic leukemia (ALL) comprises induction, consolidation, intensification, and maintenance chemotherapy. Asparaginase is a critical component during induction, consolidation and intensification in pediatric and adult/young adult populations leading to improvements in event-free and overall survival. Yet the toxicity profile of asparaginase and drug-shortages both contribute to insufficient exposure to asparaginase and suboptimal outcomes in ALL. Appropriate management of patients with ALL is challenging, particularly for adult-focused HCPs unfamiliar with pediatric and adolescent and young adults (AYA) protocols.
This CME-certified activity will focus on two trials assessing the use of blinatumomab, the first as post-reinduction therapy in LR first relapse in children and AYAa from the COG AALL1331 trial. The other considers frontline consolidation therapy for HR Philadelphia-negative ALL adult patients in the Graall-2014-QUEST trial as presented at ASH 2021.
Abstracts Discussed
A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331
Brown PA, Ji L, Xu X et al. Blood.2021;138(Supplement 1):363
Boissel N, Huguet F, Graux C, et al. Blood.2021;138(Supplement 1):1232
Faculty
Ryan D. Cassaday, MD
Associate Professor, Division of Hematology,
University of Washington School of Medicine
Associate Professor, Clinical Research Division,
Fred Hutchinson Cancer Research Center
Attending Physician, Hematologic Malignancies Program, Seattle Cancer Care Alliance
Seattle, WA
Luke Maese, DO
Associate Professor
University of Utah School of Medicine
Huntsman Cancer Institute
Primary Children's Hospital
Salt Lake City, UT
Target Audience
This education activity has been designed to meet the needs of:
Hematologists, medical oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other HCPs interested in the treatment of patients with ALL
Learning Objectives
Upon completion of this educational activity, participants should be able to:
Review of recently presented clinical trial data in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs)
Review recently presented clinical trial data in High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients
Directions to Learner
There are no fees for participating and receiving CME credit for this activity. During the period of May 23, 2022 through May 23, 2023, participants must:
Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form
A statement of credit will be issued only upon successful completion (75% passing score) and receipt of the activity posttest and evaluation form. Certificates will be sent via email within four weeks of receipt of a completed evaluation form.
Accreditation
Physician Continuing Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education, Inc. and Bonum Continuing Education LLC.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity Continuing Education, Inc. designates this Other activity (multi-channel video and discussion) for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
-
Ryan D. Cassaday, MD
Consulting: Amgen, Kite/Gilead, Pfizer
Contracted Research: Amgen, Kite/Gilead, Merck, Pfizer, Servier, Vanda Pharmaceuticals
Speaker’s Bureau: Kite/Gilead, Pfizer
DSMB Member: Pepromene BioLuke Maese, DO
Consulting: Jazz Pharmaceuticals
Speakers’ Bureau: Jazz Pharmaceuticals -
Bonum Continuing Education LLC staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Minimum System Requirements
Media: Internet
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
• Adobe® Flash® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus
For optimal performance, the use of Internet Explorer below 8 is not recommended
Privacy Policy
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Contact Information
For information about ACCME certification of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
Release date: May 23, 2022
Expiration date: May 23, 2023
Estimated time to complete activity: 30 minutes